Literature DB >> 28760230

Biochemical Testing in Thyroid Disorders.

Nazanene H Esfandiari1, Maria Papaleontiou2.   

Abstract

This article summarizes the main principles for the appropriate use of laboratory testing in the diagnosis and management of thyroid disorders, as well as controversies that have arisen in association with some of these biochemical tests. To place a test in perspective, its sensitivity and accuracy should be taken into account. Ordering the correct laboratory tests facilitates the early diagnosis of a thyroid disorder and allows for timely and appropriate treatment. This article focuses on a comprehensive update regarding thyroid-stimulating hormone, thyroxine/triiodothyronine, thyroid autoantibodies, thyroglobulin, and calcitonin. Clinical uses of these biochemical tests are outlined.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Biochemical testing; Calcitonin; TSH; Thyroglobulin; Thyroid

Mesh:

Substances:

Year:  2017        PMID: 28760230      PMCID: PMC5957513          DOI: 10.1016/j.ecl.2017.04.002

Source DB:  PubMed          Journal:  Endocrinol Metab Clin North Am        ISSN: 0889-8529            Impact factor:   4.741


  127 in total

Review 1.  Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma.

Authors:  Samuel A Wells; Sylvia L Asa; Henning Dralle; Rossella Elisei; Douglas B Evans; Robert F Gagel; Nancy Lee; Andreas Machens; Jeffrey F Moley; Furio Pacini; Friedhelm Raue; Karin Frank-Raue; Bruce Robinson; M Sara Rosenthal; Massimo Santoro; Martin Schlumberger; Manisha Shah; Steven G Waguespack
Journal:  Thyroid       Date:  2015-06       Impact factor: 6.568

2.  "Hook effect" in calcitonin immunoradiometric assay in patients with metastatic medullary thyroid carcinoma: case report and review of the literature.

Authors:  Rébecca Leboeuf; Marie-France Langlois; Marc Martin; Charaf E Ahnadi; Guy D Fink
Journal:  J Clin Endocrinol Metab       Date:  2005-11-08       Impact factor: 5.958

3.  Decreased receptor binding of biologically inactive thyrotropin in central hypothyroidism. Effect of treatment with thyrotropin-releasing hormone.

Authors:  P Beck-Peccoz; S Amr; M M Menezes-Ferreira; G Faglia; B D Weintraub
Journal:  N Engl J Med       Date:  1985-04-25       Impact factor: 91.245

4.  Thyrotropin-induced hyperthyroidism caused by selective pituitary resistance to thyroid hormone. A new syndrome of "inappropriate secretion of TSH".

Authors:  M C Gershengorn; B D Weintraub
Journal:  J Clin Invest       Date:  1975-09       Impact factor: 14.808

5.  Comparison of calcium and pentagastrin tests for the diagnosis and follow-up of medullary thyroid cancer.

Authors:  Carla Colombo; Uberta Verga; Caterina Mian; Stefano Ferrero; Michela Perrino; Leonardo Vicentini; Davide Dazzi; Giuseppe Opocher; Maria Rosa Pelizzo; Paolo Beck-Peccoz; Laura Fugazzola
Journal:  J Clin Endocrinol Metab       Date:  2011-12-14       Impact factor: 5.958

6.  2016 American Thyroid Association Guidelines for Diagnosis and Management of Hyperthyroidism and Other Causes of Thyrotoxicosis.

Authors:  Douglas S Ross; Henry B Burch; David S Cooper; M Carol Greenlee; Peter Laurberg; Ana Luiza Maia; Scott A Rivkees; Mary Samuels; Julie Ann Sosa; Marius N Stan; Martin A Walter
Journal:  Thyroid       Date:  2016-10       Impact factor: 6.568

7.  Thyrotropin levels in a population with no clinical, autoantibody, or ultrasonographic evidence of thyroid disease: implications for the diagnosis of subclinical hypothyroidism.

Authors:  Thomas E Hamilton; Scott Davis; Lynn Onstad; Kenneth J Kopecky
Journal:  J Clin Endocrinol Metab       Date:  2008-01-29       Impact factor: 5.958

8.  Hypercalcitoninemia in thyroid conditions other than medullary thyroid carcinoma: a comparative analysis of calcium and pentagastrin stimulation of serum calcitonin.

Authors:  Kerstin Lorenz; Malik Elwerr; Andreas Machens; Mohammed Abuazab; Hans-Jürgen Holzhausen; Henning Dralle
Journal:  Langenbecks Arch Surg       Date:  2013-02-14       Impact factor: 3.445

9.  Expression of thyroid hormone transporters during critical illness.

Authors:  Liese Mebis; Deborah Paletta; Yves Debaveye; Björn Ellger; Lies Langouche; André D'Hoore; Veerle M Darras; Theo J Visser; Greet Van den Berghe
Journal:  Eur J Endocrinol       Date:  2009-05-13       Impact factor: 6.664

10.  Does autoantibody-negative Graves' disease exist? A second evaluation of the clinical diagnosis.

Authors:  J Paunkovic; N Paunkovic
Journal:  Horm Metab Res       Date:  2006-01       Impact factor: 2.936

View more
  5 in total

Review 1.  Interactions between hypothalamic pituitary thyroid axis and other pituitary dysfunctions.

Authors:  Ulla Feldt-Rasmussen; Marianne Klose; Salvatore Benvenga
Journal:  Endocrine       Date:  2018-09-06       Impact factor: 3.633

2.  Screening for Thyroid Disorders Among Resistant Hypertension Patients: Are We Doing Enough?

Authors:  Nikos Pappan; Mian Tanveer Ud Din; Divya Venkat; Patrick Wedgeworth; Sheng Fu
Journal:  Clin Med Res       Date:  2022-01-07

Review 3.  Laboratory Testing in Thyroid Conditions - Pitfalls and Clinical Utility.

Authors:  Shui Boon Soh; Tar Choon Aw
Journal:  Ann Lab Med       Date:  2019-01       Impact factor: 3.464

4.  Epitopes specificity of antibodies to thyroid peroxidase in patients with Graves' disease, Hashimoto's thyroiditis and overlap-syndrome.

Authors:  Maira Espenbetova; Nina Kuzmina; Alexandr Zubkov; Venera Akhmetova; Zhanar Zamanbekova; Ainur Krykpaeva; Zhanar Zhumanbayeva; Kuralay Amrenova; Zhanargul Smailova; Natalya Glushkova
Journal:  J Clin Transl Endocrinol       Date:  2022-02-04

Review 5.  Redefinition of Successful Treatment of Patients With Hypothyroidism. Is TSH the Best Biomarker of Euthyroidism?

Authors:  Stephen P Fitzgerald; Henrik Falhammar
Journal:  Front Endocrinol (Lausanne)       Date:  2022-06-16       Impact factor: 6.055

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.